Overview

A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

Status:
Recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of moderate to severe plaque psoriasis. Additionally, this study is to find the optimal dosing for the future clinical development of HS-10374.
Phase:
Phase 2
Details
Lead Sponsor:
Hansoh BioMedical R&D Company